ISM3830 / Insilico Medicine - LARVOL DELTA

Insilico nominates ISM3830, a potentially best-in-class, orally available and highly selective CBLB inhibitor with an AI‑empowered novel scaffold, as a preclinical candidate (PCC) for advanced tumor immunotherapy (Insilico Medicine Press Release) - "In preclinical studies, ISM3830 showed robust in vivo anti‑tumor activity in multiple murine models, induction of long‑term tumor immunity, and combination potential with immune checkpoint inhibitors, chemotherapies and targeted agents. IND‑enabling studies are being initiated to support first‑in‑human evaluation in patients with advanced solid tumors."

Pipeline update • Preclinical • Solid Tumor